UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2016
|
ADMA BIOLOGICS, INC.
|
|
(Exact name of registrant as specified in its charter)
|
| |
|
|
| |
|
|
|
Delaware
|
001-36728
|
56-2590442
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
| |
|
|
| |
|
465 State Route 17 Ramsey, New Jersey
|
07446
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201) 478-5552
| |
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD.
|
Members of the management team of ADMA Biologics, Inc. (the "Company") plan to make a presentation at the Rodman & Renshaw 18th Annual Global Investment Conference at 3:00 PM ET on September 13, 2016, and at the Ladenburg Thalmann 2016 Healthcare Conference at 10:30AM ET on September 27, 2016 in New York, NY. A copy of the slide presentation that the Company intends to use is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The presentation may be accessed under the "Investor Relations" tab on the Company's website at www.admabiologics.com.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto (which has been furnished solely for this Item 7.01 and Exhibit 99.1), shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
| |
|
|
99.1
|
Slide Presentation dated September 2016.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
September 9, 2016
|
ADMA Biologics, Inc.
|
| |
|
| |
|
| |
By:
|
/s/ Brian Lenz
|
| |
|
Name:
|
Brian Lenz
|
| |
|
Title:
|
Chief Financial Officer
|
Exhibit Index
|
Exhibit No.
|
Description
|
| |
|
|
99.1
|
Slide Presentation dated September 2016.
|